Bitcoin price today: slips below $113k, near 6-wk low despite Fed cut bets
In a market that has seen its fair share of volatility, Neuraxis Inc. (NRXS) stock is trading at $2.27, with its 52-week high standing at $3.78. According to InvestingPro analysis, the company shows concerning financial health metrics, with a high Price/Book ratio of 64.4x and rapid cash burn rate. This performance comes as a notable point of interest for investors who have been tracking the company’s performance amidst a challenging economic landscape. The company has experienced a significant downturn over the past year, with a total return of -23.57%. While showing strong recent momentum, Neuraxis remains unprofitable with an EBITDA of -$7M in the last twelve months. For deeper insights into Neuraxis’s financial health and growth potential, investors can access comprehensive analysis through InvestingPro’s detailed research reports, available for over 1,400 US stocks.
In other recent news, Neuraxis Inc. reported a 39% increase in revenue for the first quarter of 2025, reaching $896,000. This growth was primarily driven by a 46% rise in unit sales, despite the company experiencing a 25% increase in operating losses, which totaled $2.3 million. Neuraxis remains debt-free with $2 million in cash on hand. The company has also expanded its insurance coverage to reach 51 million lives and received FDA label expansion for its IV Stem Technology, now covering a broader age range. Furthermore, Neuraxis anticipates accelerated revenue growth and aims for cash flow breakeven, focusing on expanding insurance policy coverage and preparing for the implementation of a Category One CPT Code in early 2026. In terms of market expansion, the company expects guidelines publication by the end of May to further support its efforts. Neuraxis is also in the middle of a soft launch for its RED device, which has received FDA clearance. These developments reflect Neuraxis’ ongoing strategic initiatives to enhance its market presence and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.